ClinicalTrials.gov
Cure8 trial brief
Why This Matters
The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and detection of precancerous lesions in people with IBD.
Who Should Pay Attention
Adults with long-standing ulcerative colitis, colonic Crohn’s disease, or IBD-U undergoing dysplasia surveillance; gastroenterologists/endoscopists; researchers focused on IBD cancer surveillance.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment1,642 participants
Study statusEnrolling_by_invitation
Source depthTrial registry record
What To Know
This is a pragmatic interventional trial enrolling adults with colonic Crohn’s disease, ulcerative colitis, or IBD-unclassified who meet surveillance criteria.
Participants are randomized to HD white-light colonoscopy with targeted biopsies plus either a small number of random biopsies by segment (limited strategy) or systematic random biopsies every ~10 cm (random strategy).
The primary outcome is the number of dysplastic or SSA lesions detected per colonoscopy at the index procedure; follow-up by chart review may continue for many years.
The study is designed to answer a practical question about the added value, patient risk, and cost-effectiveness of routine random biopsies during surveillance colonoscopy when high-definition scopes are used. It does not test imaging technologies (eg, virtual chromoendoscopy) as the intervention but compares biopsy sampling strategies.
Keep In Mind
This is a trial registration (interventional, enrolling by invitation) and does not present results. The primary outcome is lesion detection at the index colonoscopy; long-term follow-up by chart review is planned. The protocol excludes patients with incompletely resected prior dysplasia/SSA or prior colorectal cancer.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAbramson Cancer Center at Penn Medicine
Trial IDNCT06560021
Study typeInterventional
Trial phaseNA
Enrollment1,642 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 17, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Intestinal Ultrasound Guided Management in Inflammatory Bowel Disease
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
IBD colorectal guidelines
People with IBD have a higher lifetime risk of colorectal cancer; updated UK guidelines give clinicians and patients evidence-based recommendations on when and how to do surveillance colonoscopy to detect precancerous...